The effect of treatment of soybean meal on the availability of amino acids and the efficiency of nitrogen usage for milk production in dairy cows /

In the first of three experiments, four Holstein multiparous dairy cows, equipped with ruminal and duodenal cannulas, were used to determine the impact of different methods of treating soybean meal (SBM) on ruminal degradability and intestinal digestibility of CP and amino acids (AA). Solvent extracted SBM (SE), expeller SBM (EP), lignosulfonate SBM (LS) and heat and soy hulls SBM (HS) were incubated in the rumen, in nylon bags, for various intervals up to 48h. Additional samples incubated for 16 h were pre-treated with pepsin HCI, and then used for determination of intestinal digestibility either in situ (mobile bag technique) or in vitro. Treatment of SBM (EP, LS, HS) increased rumen undegradable protein (RUP), and AA availability in 30%. Estimates of intestinal digestibility of AA and CP were lower when measured in vitro than in situ. Among the treated SBM products, four EAA (Ile, Leu, Phe and Val) showed differences in availability, with values consistently lower for HS than for LS. The second experiment involved a comparative assessment of the availability of lysine in SE and rumen protected SBM products (EP and LS). Lysine availability was assessed either by the increment in plasma flux of 15N lysine, the increment in intestinally digestible lysine (using chromic oxide as a digesta marker) or by the use of a "plasma lysine response curve" designed to predict intestinally available lysine. The plasma Lys flux was not different between the different SBM products. However, SE + 70 g.d-1 omasal infusion of Lys (SE70) increased Lys flux by exactly 70 g.d -1 above the SE treatment. No differences were observed on duodenal Lys flow, post-ruminal digestion and digestible Lys between the SBM diets (SE, EP, LS). Irrespective of the method of assessment, lysine availability was not altered by the method of treating SBM. The third study evaluated the relative impact of supplying rumen-undegraded protein (RUP) versus altering the carbohydrate source on milk yield and efficiency N usage for milk production. Protein supplementation (SE and EP) increased DMI, whereas the inclusion of beet pulp (BP) replacing 50% of high moisture shelled corn decreased DMI. The results of this research suggest that, under normal conditions of feeding, supplying rumen protected SBM to enhance the supply of intestinally available essential AA does not improve lactation performance; providing beet pulp as a source of readily fermentable fibre also failed to affect milk yield or efficiency of N usage for milk production by dairy cattle

Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous, based on a dossier submitted by Calibre Europe SPRL/BVBA

Calcium iodate anhydrous is considered a safe source of iodine for all animal species/categories when used up to the currently authorised maximum content of total iodine in complete feed, with the exception of horses and dogs, for which maximum tolerated levels are 3 and 4 mg I/kg complete feed, respectively. The limited data available on iodine tolerance in cats support a provisional tolerated level of 5 mg I/kg complete feed. Exposure of consumers was calculated in two scenarios applying the currently authorised maximum iodine contents in feed and reduced contents. The iodine content of food of animal origin, if produced taking account of the currently authorised maximum content of iodine in feed, would represent a substantial risk to high consumers. The risk would originate primarily from the consumption of milk and to a minor extent from eggs. The UL for adults (600 µg/day) and for toddlers (200 µg/day) would be exceeded by a factor of 2 and 4, respectively. If the authorised maximum iodine concentrations in feed for dairy cows and laying hens were reduced to 2 and 3 mg I/kg feed, respectively, the exposure of adult consumers would be below the UL. However, iodine intake in high-consuming toddlers would remain above the UL (1.6-fold). Calcium iodate is considered as irritant to the eye, skin and respiratory tract, and a dermal sensitiser. The exposure by inhalation should be avoided. The use of calcium iodate in animal nutrition is not expected to pose a risk to the environment. Calcium iodate is efficacious to meet animal iodine requirements. The FEEDAP Panel recommends that the maximum iodine contents in complete feed be reduced as follows: dairy cows and minor dairy ruminants, 2 mg I/kg; laying hens, 3 mg I/kg; horses, 3 mg I/kg; dogs, 4 mg I/kg; cats, 5 mg I/kg

The PLATO 2.0 mission

PLATO 2.0 has recently been selected for ESA's M3 launch opportunity (2022/24). Providing accurate key planet parameters (radius, mass, density and age) in statistical numbers, it addresses fundamental questions such as: How do planetary systems form and evolve? Are there other systems with planets like ours, including potentially habitable planets? The PLATO 2.0 instrument consists of 34 small aperture telescopes (32 with 25 s readout cadence and 2 with 2.5 s candence) providing a wide field-of-view (2232 deg 2) and a large photometric magnitude range (4-16 mag). It focusses on bright (4-11 mag) stars in wide fields to detect and characterize planets down to Earth-size by photometric transits, whose masses can then be determined by ground-based radial-velocity follow-up measurements. Asteroseismology will be performed for these bright stars to obtain highly accurate stellar parameters, including masses and ages. The combination of bright targets and asteroseismology results in high accuracy for the bulk planet parameters: 2 %, 4-10 % and 10 % for planet radii, masses and ages, respectively. The planned baseline observing strategy includes two long pointings (2-3 years) to detect and bulk characterize planets reaching into the habitable zone (HZ) of solar-like stars and an additional step-and-stare phase to cover in total about 50 % of the sky. PLATO 2.0 will observe up to 1,000,000 stars and detect and characterize hundreds of small planets, and thousands of planets in the Neptune to gas giant regime out to the HZ. It will therefore provide the first large-scale catalogue of bulk characterized planets with accurate radii, masses, mean densities and ages. This catalogue will include terrestrial planets at intermediate orbital distances, where surface temperatures are moderate. Coverage of this parameter range with statistical numbers of bulk characterized planets is unique to PLATO 2.0. The PLATO 2.0 catalogue allows us to e.g.: - complete our knowledge of planet diversity for low-mass objects, - correlate the planet mean density-orbital distance distribution with predictions from planet formation theories,- constrain the influence of planet migration and scattering on the architecture of multiple systems, and - specify how planet and system parameters change with host star characteristics, such as type, metallicity and age. The catalogue will allow us to study planets and planetary systems at different evolutionary phases. It will further provide a census for small, low-mass planets. This will serve to identify objects which retained their primordial hydrogen atmosphere and in general the typical characteristics of planets in such low-mass, low-density range. Planets detected by PLATO 2.0 will orbit bright stars and many of them will be targets for future atmosphere spectroscopy exploring their atmosphere. Furthermore, the mission has the potential to detect exomoons, planetary rings, binary and Trojan planets. The planetary science possible with PLATO 2.0 is complemented by its impact on stellar and galactic science via asteroseismology as well as light curves of all kinds of variable stars, together with observations of stellar clusters of different ages. This will allow us to improve stellar models and study stellar activity. A large number of well-known ages from red giant stars will probe the structure and evolution of our Galaxy. Asteroseismic ages of bright stars for different phases of stellar evolution allow calibrating stellar age-rotation relationships. Together with the results of ESA's Gaia mission, the results of PLATO 2.0 will provide a huge legacy to planetary, stellar and galactic science

Margarita de Sossa, Sixteenth-Century Puebla de los Ángeles, New Spain (Mexico)

Margarita de Sossa’s freedom journey was defiant and entrepreneurial. In her early twenties, still enslaved in Portugal, she took possession of her body; after refusing to endure her owner’s sexual demands, he sold her, and she was transported to Mexico. There, she purchased her freedom with money earned as a healer and then conducted an enviable business as an innkeeper. Sossa’s biography provides striking insights into how she conceptualized freedom in terms that included – but was not limited to – legal manumission. Her transatlantic biography offers a rare insight into the life of a free black woman (and former slave) in late sixteenth-century Puebla, who sought to establish various degrees of freedom for herself. Whether she was refusing to acquiesce to an abusive owner, embracing entrepreneurship, marrying, purchasing her own slave property, or later using the courts to petition for divorce. Sossa continued to advocate on her own behalf. Her biography shows that obtaining legal manumission was not always equivalent to independence and autonomy, particularly if married to an abusive husband, or if financial successes inspired the envy of neighbors

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Altering electrolyte balance of diets for lactating dairy cows to reduce phosphorus excretion to the environment

The study was designed to test the hypothesis that P excretion in manure of dairy cattle could be reduced by manipulating electrolyte balance of the diet. Feces was the main route of P excretion, but fecal P was not affected by dietary cation-anion (DCAB) (P > 0.05). Plasma concentration of P tended (P < 0.10) to be higher at lower DCAB levels, implying that DCAB may have influenced P homeostasis. The overall P balance was not affected by the different DCAB levels. The range of DCAB where both P excretion and animal performance could be optimised is very narrow (+250 to +350 mEq/kg DM), so using DCAB to control P excretion in dairy cattle requires caution. (Abstract shortened by UMI.